Fei Li

Dr. Fei Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Cancer Cell
Verified
Journal Article
Closed access
CZCaicun Zhou
Caicun Zhou
CLChongyang Li
Chongyang Li
LLLibo Luo
Libo Luo
XLXin Li
Xin Li
KJKeyi Jia
Keyi Jia
SRShengxiang Ren
Shengxiang Ren

30 August 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
HHHai Hu
Hai Hu
AKAlireza Khodadadi-Jamayran
Alireza Khodadadi-Jamayran
IDIgor Dolgalev
Igor Dolgalev
HCHyunwoo Cho
Hyunwoo Cho
SBSana Badri
Sana Badri
KWKwok-Kin Wong
Kwok-Kin Wong
Substantial progress has been made in understanding how tumors escape immune surveillance. However, few measures to counteract tumor immune evasion have been developed. Suppression of tumor antigen expression is a common adaptive mechanism that cancers use to evade detection and destruction by the immune system. Epigenetic modifications play a critical role in various aspects of immune invasion, including the regulation of tumor antigen expression. To identify epigenetic regulators of tumor antigen expression, we established a transplantable syngeneic tumor model of immune escape with silenced antigen expression and used this system as a platform for a CRISPR–Cas9 suppressor screen for genes encoding epigenetic modifiers. We found that disruption of the genes encoding either of the chromatin modifiers activating transcription factor 7–interacting protein (Atf7ip) or its interacting partner SET domain bifurcated histone lysine methyltransferase 1 (Setdb1) in tumor cells restored tumor antigen expression. This resulted in augmented tumor immunogenicity concomitant with elevated endogenous retroviral (ERV) antigens and mRNA intron retention. ERV disinhibition was associated with a robust type I interferon response and increased T-cell infiltration, leading to rejection of cells lacking intact Atf7ip or Setdb1. ATF7IP or SETDB1 expression inversely correlated with antigen processing and presentation pathways, interferon signaling, and T-cell infiltration and cytotoxicity in human cancers. Our results provide a rationale for targeting Atf7ip or Setdb1 in cancer immunotherapy.

4 February 2022 in Science Advances
Verified
Journal Article
Open access
QHQingyuan Huang
Qingyuan Huang
FLFei Li
Fei Li
HHHai Hu
Hai Hu
ZFZhaoyuan Fang
Zhaoyuan Fang
ZGZhendong Gao
Zhendong Gao
KWKwok-Kin Wong
Kwok-Kin Wong
Tuberous sclerosis complex subunit 1 ( TSC1 ) and 2 ( TSC2 ) are frequently mutated in non–small cell lung cancer (NSCLC), however, their effects on antitumor immunity remained unexplored. A CRISPR screening in murine Kras G12D / Trp53 −/− (KP) model identified Tsc1 and Tsc2 as potent regulators of programmed cell death ligand 1 (Pd-l1) expression in vitro and sensitivity to anti–programmed cell death receptor 1 (PD-1) treatment in vivo. TSC1 or TSC2 knockout (KO) promoted the transcriptional and membrane expression of PD-L1 in cell lines. TSC2 -deficient tumors manifested an inflamed microenvironment in patient samples and The Cancer Genome Atlas dataset. In syngeneic murine models, KP- Tsc2 -KO tumors showed notable response to anti–PD-1 antibody treatment, but Tsc2 –wild-type tumors did not. Patients with TSC1 / TSC2 -mutant NSCLC receiving immune checkpoint blockade (ICB) had increased durable clinical benefit and survival. Collectively, TSC1 / TSC2 loss defines a distinct subtype of NSCLC characterized as inflamed tumor microenvironment and superior sensitivity to ICB.

13 February 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
TDTanner J. DuCote
Tanner J. DuCote
XSXiulong Song
Xiulong Song
KNKassandra J. Naughton
Kassandra J. Naughton
FCFan Chen
Fan Chen
DPDaniel R. Plaugher
Daniel R. Plaugher
CUChristine UK
Christine UK
Two important factors that contribute to resistance to immune checkpoint inhibitors (ICI) are an immune-suppressive microenvironment and limited antigen presentation by tumor cells. In this study, we examine whether inhibition of the methyltransferase enhancer of zeste homolog 2 (EZH2) can increase ICI response in lung squamous cell carcinomas (LSCC). Our in vitro experiments using two-dimensional human cancer cell lines as well as three-dimensional murine and patient-derived organoids treated with two inhibitors of the EZH2 plus IFNγ showed that EZH2 inhibition leads to expression of both MHC class I and II (MHCI/II) expression at both the mRNA and protein levels. Chromatin immunoprecipitation sequencing confirmed loss of EZH2-mediated histone marks and gain of activating histone marks at key loci. Furthermore, we demonstrate strong tumor control in models of both autochthonous and syngeneic LSCC treated with anti-PD1 immunotherapy with EZH2 inhibition. Single-cell RNA sequencing and immune cell profiling demonstrated phenotypic changes toward more tumor suppressive phenotypes in EZH2 inhibitor–treated tumors. These results indicate that EZH2 inhibitors could increase ICI responses in patients undergoing treatment for LSCC. Significance: The data described here show that inhibition of the epigenetic enzyme EZH2 allows derepression of multiple immunogenicity factors in LSCC, and that EZH2 inhibition alters myeloid cells in vivo. These data support clinical translation of this combination therapy for treatment of this deadly tumor type.

29 January 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZQZhen Qin
Zhen Qin
MYMeiting Yue
Meiting Yue
STShijie Tang
Shijie Tang
FWFengying Wu
Fengying Wu
HSHonghua Sun
Honghua Sun
HJHongbin Ji
Hongbin Ji
Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is detectable in 5.1–7.5% of human LUAS, and transgenic expression of EML4-ALK drives lung adenocarcinoma (LUAD) formation initially and squamous transition at late stage. We identify club cells as the main cell-of-origin for squamous transition. Through recapitulating lineage transition in organoid system, we identify JAK-STAT signaling, activated by EML4-ALK phase separation, significantly promotes squamous transition. Integrative study with scRNA-seq and immunostaining identify a plastic cell subpopulation in ALK-rearranged human LUAD showing squamous biomarker expression. Moreover, those relapsed ALK-rearranged LUAD show notable upregulation of squamous biomarkers. Consistently, mouse squamous tumors or LUAD with squamous signature display certain resistance to ALK inhibitor, which can be overcome by combined JAK1/2 inhibitor treatment. This study uncovers strong plasticity of ALK-rearranged tumors in orchestrating phenotypic transition and drug resistance and proposes a potentially effective therapeutic strategy.

10 May 2024 in Cancer Letters
Verified
Journal Article
Closed access
ZWZheyi Wang
Zheyi Wang
YZYue Zhao
Yue Zhao
YWYang Wo
Yang Wo
YPYizhou Peng
Yizhou Peng
WHWeilei Hu
Weilei Hu
YSYihua Sun
Yihua Sun